Turning Point Brands Beats Q2 Sales by 11%, Raises Modern Oral Guidance
TPB sits 28% above its 52-week low of $65.8.
Summary
Q2 sales surged 23% to $143M, well above the $129M consensus, driven by Modern Oral products now accounting for nearly half of total sales. Adjusted EPS of $0.23 missed estimates by a wide margin as SG&A spending nearly doubled to support brand and distribution investments. Management raised full-year Modern Oral gross sales guidance to $330-$350M and net sales to $260-$270M, signaling confidence in sustained momentum. The one-time tariff refund flattered gross profit, but underlying growth remains strong. This follows a Q1 beat and the recent European launch of the ALP brand, reinforcing the Modern Oral growth narrative.
At the time of this announcement, TPB was trading at $84.50 on NYSE in the Trade & Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $65.80 to $146.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.